Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Moleculin Biotech, Inc. (MBRX)

Moleculin Completes Part A Dosing in MIRACLE Trial; Q1 2027 Data Readout on Track

Neutral Impact 3 of 5 product/contract Written later

Moleculin Biotech announced that dosing is complete in Part A of its pivotal Phase 2/3 MIRACLE trial of Annamycin with cytarabine for relapsed or refractory acute myeloid leukemia. The company says it remains on track to report comprehensive Part A data in the first quarter of 2027, with the full 90-patient population used to select the Annamycin dose for Part B.

Key points

  • Dosing completed in Part A of the MIRACLE trial, which the company describes as a randomized, double-blind study with a 90-patient Part A population.
  • Comprehensive Part A data readout remains expected in the first quarter of 2027.
  • Final Part A population is expected to be about 50/50 between 7+3 chemotherapy and venetoclax-based regimen patients, versus about 70/30 among the first 45 subjects.
  • The filing states the company will require significant additional financing, for which it has no commitments.

The filing

CompanyMoleculin Biotech, Inc. (MBRX)
Form8-K, current report
Filed with the SECOct 30, 2026, 8:50 AM ET
Accession number0001437749-26-034075

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 30, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.